Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary.

Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource biologicals for treatment naive patients and promoting use of more affordable multisource biologicals in case of switching. PMID: 31510811 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research